Evaluation of Pharmacologic Treatments for H1 Antihistamine–Refractory Chronic Spontaneous Urticaria

医学 梅德林 奇纳 抗组胺药 随机对照试验 科克伦图书馆 安慰剂 内科学 数据提取 荟萃分析 临床试验 物理疗法 儿科 心理干预 替代医学 精神科 药理学 病理 法学 政治学
作者
Surapon Nochaiwong,Mati Chuamanochan,Chidchanok Ruengorn,Ratanaporn Awiphan,Napatra Tovanabutra,Siri Chiewchanvit
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:157 (11): 1316-1316 被引量:25
标识
DOI:10.1001/jamadermatol.2021.3237
摘要

The comparative benefits and harms of all available treatments for H1 antihistamine-refractory chronic spontaneous urticaria (CSU) have not been established.To evaluate different treatment effects of pharmacologic treatments among patients with H1 antihistamine-refractory CSU.Searches were conducted of MEDLINE, Embase, PubMed, Cochrane Library, Web of Science, Scopus, and CINAHL from inception to April 19, 2021, with no language restrictions. Gray literature from Google Scholar, ongoing trial registers, and preprint reports was added to the searches of electronic databases.Randomized clinical trials using validated measurement tools that investigated the benefits and harms of pharmacologic treatments among adolescent or adult patients with CSU who had an inadequate response to H1 antihistamines were screened for inclusion independently by 2 investigators.Two investigators independently extracted study data according to the predefined list of interests. A random-effects model was used to calculate the network estimates reported as standardized mean differences and odds ratios with corresponding 95% CIs.The primary outcomes that reflect the patient's perspective included changes in urticaria symptoms from baseline and unacceptability of treatment (all-cause dropouts).Twenty-three randomized clinical trials with 2480 participants that compared 18 different interventions or dosages and placebo were included. The standardized mean differences for change in urticaria symptoms were -1.05 (95% CI, -1.37 to -0.73) for ligelizumab, 72 mg; -1.07 (95% CI, -1.39 to -0.75) for ligelizumab, 240 mg; -0.77 (95% CI, -0.91 to -0.63) for omalizumab, 300 mg; and -0.59 (95% CI, -1.10 to -0.08) for omalizumab, 600 mg. No significant differences in treatment unacceptability were observed. With respect to benefits and harms, the network estimates illustrated that the most efficacious treatments were achieved with ligelizumab, 72 or 240 mg (large beneficial effect) and omalizumab, 300 or 600 mg (moderate beneficial effect).The findings in this meta-analysis suggest that the biologic agents ligelizumab, 72 or 240 mg, and omalizumab, 300 or 600 mg, can be recommended as effective treatments for patients with CSU who have had an inadequate response to H1 antihistamines. Head-to-head trials with high methodologic quality and harmonized design and outcome definitions are needed to help inform subsequent international guidelines for the management of CSU.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大力听芹完成签到,获得积分10
1秒前
毛毛完成签到,获得积分10
4秒前
Hiram完成签到,获得积分10
12秒前
zyb完成签到 ,获得积分10
16秒前
朱科源啊源完成签到 ,获得积分10
21秒前
轩辕唯雪发布了新的文献求助30
22秒前
诸青梦完成签到 ,获得积分10
24秒前
26秒前
victory_liu完成签到,获得积分10
30秒前
Owen应助U9A采纳,获得10
31秒前
鲲鹏完成签到 ,获得积分10
31秒前
32秒前
CNYDNZB完成签到 ,获得积分10
33秒前
Harlotte完成签到 ,获得积分10
40秒前
fjmelite完成签到 ,获得积分10
40秒前
CYYDNDB完成签到 ,获得积分10
41秒前
Serein完成签到,获得积分10
44秒前
Jasper应助阔达的棒棒糖采纳,获得10
44秒前
勤劳的老九应助轩辕唯雪采纳,获得10
46秒前
水晶李完成签到 ,获得积分10
49秒前
Bismarck发布了新的文献求助10
55秒前
58秒前
smottom应助轩辕唯雪采纳,获得20
1分钟前
晨许沫光发布了新的文献求助10
1分钟前
所所应助玄学小生采纳,获得10
1分钟前
研友_Ljqal8完成签到,获得积分10
1分钟前
JACK完成签到,获得积分10
1分钟前
清修完成签到,获得积分10
1分钟前
健忘的晓小完成签到 ,获得积分10
1分钟前
1分钟前
犹豫野狼完成签到 ,获得积分10
1分钟前
1分钟前
传奇3应助U9A采纳,获得10
1分钟前
晨许沫光完成签到 ,获得积分10
1分钟前
柒八染完成签到 ,获得积分10
1分钟前
1分钟前
Bryan应助疯狂的向日葵采纳,获得10
1分钟前
酷酷的涵蕾完成签到 ,获得积分10
1分钟前
1分钟前
朱比特完成签到,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968559
求助须知:如何正确求助?哪些是违规求助? 3513358
关于积分的说明 11167368
捐赠科研通 3248732
什么是DOI,文献DOI怎么找? 1794465
邀请新用户注册赠送积分活动 875065
科研通“疑难数据库(出版商)”最低求助积分说明 804664